SOFIVA GENOMICS

Stock Code 6615

Investor Conference

2024 / 12 / 18

Chairman
Yi-Ning Su, MD. Ph.D

Disclaimer

All statements for investors contain information that represent, other than historical facts, SOFIVA's plans and forward-looking statements are based upon management's current assumptions.

Environmental changes and other important factors could cause actual results to differ materially from those expressed in our statements.

Investors should carefully consider the investment objectives and risks before investing.

SOFIVA
GENOMICS

SOFIVA - The Dual Operating Strategy

Maternal Fetal Medicine | **Precision Cancer Medicine**

Genetic Screening Category	Servicing Specialty	Target
Reproductive	IVF Center	IVF Embryo Screening
Prenatal	OB-GYN	Pre-pregnant couples Pregnant couples
Newborn	Pediatrics, Neonatology	Child Newborn
Cancer	Cancer-related Specialty	All Target Audience (Pre-Cancer & Patient)
Rare Disease	Genetics-related Specialty	All Target Audience
Precision Medicine	Treatment-related Specialty	All Target Audience

SOFIVA GENOMICS

Protecting Life and Health with 6 Core Testing Services

Preconception

About 50,000 Cycles per Year

Gestation

About 130,000 People per Year

Neonatal

About 130,000 People per Year

Healthy

Cancer Patient

About 120,000 New Cancer Cases per Year

Reproductive

Cancer

Prenatal

Precision Medicine

Newborn

Rare Disease

Maternal Fatal Medicine and Precision Cancer Medicine One Stop Service

Reproductive

- PGT-M
- PGT-A
- niPGT-A

Rare Diseases

- Hearing Loss Genetic Test v1.0/v2.0/v3.0
- Achondroplasia
- Osteogenesis Imperfecta
- Duchenne Muscular Dystrophy
- Wilson's Disease
- Marfan Syndrome
- Whole Exon Sequencing Genetic Testing

Prenatal

- NIPS
- Array
- Karyotyping
- Carrier Scan
- SMA Genetic Testing-SMN gene
- Fragile X Genetic Testing-FMR1 gene
- Thalassemia Genetic Testing-HBA,HBB gene
- Folate Metabolism Genetic Testing-MTHFR gene

Cancer

- Cancer Monitor
- Cancer Scan v1.0/v2.0
- Cancer Risk v1.0/v2.0
- HPV Screening

Newborn

- Baby Scan
- Hearing Loss Genetic Screening
- CCHS Genetic Screening
- Congenital CMV Infection Screening
- Atopic Dermatitis Genetic Screening -FLG gene

Precision Medicine

- HRD Status
- CGP Genetic Test
- BRCA1/2 Genetic Testing
- Endometrial Cancer Genetic Subtypes
- Prostate Cancer Genetic Testing

SOFIVA GENOMICS

Operating Strategy

SOFIVA
GENOMICS

The Impact of Declining Birth Rates



National Development Council
Population Projections for the R.O.C. (Taiwan)

Source: National Development Council

SOFIVA GENOMICS

Impact of Declining Birth Rates on Revenue

113Q3 compared to 112Q3





Focus on Advancing High-Level Projects on Revenue

113Q3 compared to 112Q3

Prenatal

Carrier Scan v2.0/v3.0

Growth 8%

112 Q2 | 112 Q3 | 112 Q4 | 113 Q1 | 113 Q2 | 113 Q3

Prenatal

Array v2.0/v3.0

Growth 11%

112 Q2 | 112 Q3 | 112 Q4 | 113 Q1 | 113 Q2 | 113 Q3

Newborn

Baby Scan v2.0/v3.0

Growth 35%

112 Q2 | 112 Q3 | 112 Q4 | 113 Q1 | 113 Q2 | 113 Q3

The goal is to boost revenue per capita from testing.

We will refine market direction and promotion.

Cancer Products Aligned with Clinical Requirements

1. Clinical Institutions

Partner Institutions: Over 190 Hospitals and Clinics

Medical Centers: Over 10
Regional Hospitals: Over 100



	品項	基因數	檢體	特色	適用科別
1	子宮內膜癌基因分型	6	組織+血液	市場獨家: 子宮內膜癌治療	婦科
2	癌監控基因檢測-膽管癌	13	組織 or 血液	膽管癌: FDA用藥+臨床試驗用藥	消化
3	癌監控基因檢測-泌尿道上皮癌	13	組織 or 血液	泌尿道上皮癌: FDA用藥+臨床試驗用藥	泌尿
4	癌監控基因檢測-肺癌	26	組織 or 血液	肺癌: FDA用藥+臨床試驗用藥	胸腔
5	癌監控基因檢測-乳癌	26	組織 or 血液	乳癌: FDA用藥+臨床試驗用藥	乳外
6	癌監控基因檢測-大腸癌	26	組織 or 血液	大腸癌: FDA用藥+臨床試驗用藥	直外
7	HRD檢測	28	組織+血液	在台灣已收案1000多案例	婦科/乳外/泌尿
8					
9					
10				可用液態	用藥
11				全球第一套	藥用藥
12					
13	癌風險-大腸癌基因檢測				
14	癌風險-婦癌基因檢測				
15	癌風險基因檢測 v1.0	67	組織 or 血液	各癌別	全科別
16	癌風險基因檢測 v2.0	151	組織 or 血液	各癌別	全科別
17	癌監控基因檢測 v2.2	197	組織+血液	全方位: FDA用藥+復發相關基因	全科別
18	癌監控基因檢測 v3.0	249	組織+血液	全方位: FDA用藥+臨床試驗用藥+復發相關基因	全科別

Multiple Products

Multiple Sample Types

Unique Testing Features

Wide Range of Applicable Specialties

Cancer Products Compliant with Government Policies

2. NGS Genetic Laboratory - Accredited Laboratory Operations

Compliant with the Qualifications and Standards of the Regulations on Special Medical Techniques


衛生福利部食品藥物管理署

精準醫療分子檢測實驗室列冊登錄資料

機構名稱：慧智基因醫事檢驗所(地址：臺北市中正區寶慶路27號6樓、8樓)

機構負責人：連喆淨

實驗室名稱：慧智基因醫學實驗室(地址：臺北市中正區寶慶路27號)

實驗室負責人：

列冊登錄編號：

列冊有效期限：

列冊範圍：

項次				
1	非侵入			
2	次世代 染色體			
3	癌症	2. 基因數：249（附表1）		

LDTS Registration


Taiwan Accreditation Foundation

認證證書

(證書編號：L4062-230401)

茲證明

慧智基因醫事檢驗所

慧智基因醫學實驗室

台北市中正區寶慶路27號(6樓、8樓)

為本會認證之實驗室

認證依據：ISO 15189：2012

認證編號：4062

初次認證日期：一百一十二年三月二十八日

認證有效期間：一百一十二年三月二十八日至一百一十五年三月二十七日止

連喆淨

中華民國一一二年四月一日

第1頁，共1頁

ISO15189

Pathological Slides

Biological Analysis

Report Consultation

Report Discussion

SOFIVA GENOMICS

3. NGS Genetic Testing

Laboratory and Testing Compliant with NGS Health Insurance Coverage

Over Ten Types of Tests

14 Types
Solid Tumors

5 Types
Hematologic Cancers

Compliant with Health Insurance Coverage Criteria for Various Cancer Types

BRCA1/2 Genetic Testing	Coverage of $10,000 TWD
Small Panel ≤100 genes	Coverage of $20,000 TWD
Large Panel > 100 genes	Coverage of $30,000 TWD

Current Status of Cancer Product Review

次世代基因定序檢測實驗室審查慢 醫事司：改電子化

2024-10-21 03:49 聯合報／記者沈能元／台北報導 ＋腫瘤

「次世代基因定序檢測」（ＮＧＳ）上路後，可望讓晚期癌友獲得精準治療，但成效卻不如預期，一位不具名腫瘤科醫師表示，部分關鍵在於實驗室開發檢測（ＬＤＴｓ）核准速度太慢，建議明文規定適當審查期限，讓醫療院所掌握完成時間。

義大癌治療醫院副院長饒坤銘表示，ＮＧＳ採「事前報備、事後審查」制度，一旦癌友血液上，

The Laboratory Review Process is Experiencing Delays

饒坤銘表示，就院方來說，若並非檢體瑕疵，造成檢測後無法找到突變基因，應算有效檢測。除非是檢體瑕疵，無法完成檢測才給予退費，醫院應先與病人說明溝通。建議健保署盤點ＮＧＳ審查、收費、退費等流程，使其更為流暢，並讓更多醫院加入檢測，才能提高服務量能，「不要讓病人想做，卻沒得

衛福部醫事司副司長劉玉菁指出，實驗室開發

納入特管辦法前的送審個案均已審查完畢，

八一件，仍有四二八四件待審。為加速審查作業

件採電子化，節省人工審查及書面往來時間，期望送檢案件儘速完成審查。

NGS給付累計842件、肺癌最多 台大癌醫院長曝有1限制

2024-11-16 10:50 聯合報／記者林琮恩／台北即時報導 ＋肺癌

As of Now, Only 842 Applications Have Been Approved

Testing Items Awaiting Simplified Review

第一，其次為卵巢／輸卵管／腹膜癌共155

肝內膽管癌63件，胰臟癌16件，甲狀腺癌12

共163件，小於100基因的「小套組」247件，

BRCA 1／2基因檢測為最多，共432件。

Cancer Product Response Strategies

Slow Review Process

Establish a Dedicated Team to Handle the Process

Accelerate Data Processing

Monitor the Review Process Speed

Health Insurance Coverage for NGS

Breast Cancer

Ovarian Cancer

Lung Cancer

Pancreatic Cancer

Cholangiocarcinoma

Prostate Cancer

Focus on Key Tests Covered by Health Insurance for NGS

BRCA

HRD

CGP

MSI

Series of Lung Cancer Tests

Series of Cancer Monitor

Testing Items Awaiting Simplified Review

In Response to the High Demand for Health Insurance Coverage of NGS

In Response to the Demand for Health Insurance Coverage of Medications

Strengthen Cross-Industry Alliances

Focus on Key Tests Covered by Health Insurance for Medications

Pharmaceutical Partners

AstraZeneca

janssen

BAYER

Takeda

AMGEN

SOFIVA

Pfizer

Review Process and Progress



Strategic Expansion into the Health Check-up Market

Cancer: The Leading Cause of Death

Top 10 Cancer Causes of Death

In 2021, 120,000 New Cancer Cases (Published in 2023)
In 2023, 50,000 Cancer Deaths (Published in 2024)

Lung Cancer | Liver Cancer | Colorectal Cancer | Breast Cancer | Prostate Cancer

Early Cancer Screening Reduces Mortality Risk by up to 70%
MOHW to Increase Early Cancer Screening Budget in 2025 (from 2.8 Billion to 6.8 Billion)

Oral Cancer | Pancreatic Cancer | Stomach Cancer | Esophageal Cancer | Ovarian Cancer





Source: MOHW, Department of Statistics

Strengthen the National Cancer Prevention and Control Program

早期癌篩、新藥基金、精準醫療 目標2030年癌死降三分之一

2024-11-29 02:40 聯合報／記者周佑政、廖靜清、賴昀岫／台北報導

總統府健康台灣推動委員會第二次會議昨天登場，衛福部提出「強化癌症防治策略」報告。圖／擷取自總統府YT頻道

- Enhance Early Cancer Screening
- Provide Coverage for Cancer Genetic Testing
- Increase Cancer New Drug Fund by Billions

Reduce Cancer Mortality Rate by One-Third by 2030

Health Check-up Market Size

衛生福利部國民健康署
Health Promotion Administration, Ministry of Health and Welfare

Utilization Rate of Preventive Health Services Among Taiwanese Adults





40-64yrs	Ages 40-64: Eligible for Screening Every 3 Years
Qualified Individuals Tested	3,035,023
Utilized Population	843,280
Service Utilization Rate	27.8%

>65yrs	Ages 65 and Above: Eligible for One Screening per Year
Qualified Individuals Tested	4,085,793
Utilized Population	1,054,877
Service Utilization Rate	25.8%

Source : Executive Yuan Gender Equality Committee; National Health Insurance Administration, 2022 Adult Preventive Health Services Payment Data File; Ministry of the Interior Population Statistics (Year-End Population)

SOFIVA GENOMICS

Health Checkup Market : Product Expansion

Preconception

Available for All Specialties: Access to Preconception Screening with Seamless Referral After Screening

Female

In Line with Regular Health Insurance Screenings, Early Screening for Women's Cancers is Crucial

Male

In Line with Regular Health Insurance Screenings, Early Screening for Men's Cancers is Crucial

Elderly

Health Management for the Elderly Population: Focus on Cancer, Aging, and Dementia

Comprehensive and Precise Health

Carrier Scan | Cancer Scan | Cancer Risk | APOE Genetic Testing

SOFIVA GENOMICS

The world ‘s top medical journals NEJM

NIPS / NIPT

Suspected Maternal Cancer

cfDNA Result

Unable to Analyze Chromosomal Aneuploidy

Failure Report

No Cancer Symptoms in the Pregnant Woman



52 People With Cancer

107 People Unable to Analyze

MRI



cfDNA Whole Genome Sequencing

Other Laboratory Tests

Strategic Expansion into the Health Check-up Market

Cancer Scan

Liquid Biopsy

Cancer Screening

What is Liquid Biopsy? Circulating Tumor DNA (ctDNA)



Cancer Cell

Normal Cell

Cell Death

Short DNA fragments
NGS Technology
Identify cancer gene mutations

Blood (Urine/Ascites...)





Br J Pharm(1):3-18. *Mol Diagn Ther* 2019; 23(3):311-331. *Chonnam Med J* 2016; 52(3): 151–158.

Cancer Screening

The Advantages of Using ctDNA) for Cancer Screening



The Innovation 3(4): 100259, July 12, 2022

Liquid Biopsy

- Can detect early-stage cancer
- Can provide information on multiple types of cancer simultaneously
- A simple blood draw is sufficient
- Provide genetic information about the tumor

Traditional Cancer Screening

- Less sensitive
- Targets only one type of cancer at a time
- Some cancers do not have suitable detection methods
- Mostly invasive testing
- Cannot provide genetic information about the tumor

SOPHIA GENOMICS

SOFIVA Blood Testing

Genetic Mutations + Cancer Screening + Cancer Recurrence

Healthy Individual | Diagnosis | Surgery (Treatment)

Hereditary Genetic Testing

Family Genetic Testing

Blood

Liquid Biopsy

ctDNA

ctDNA

Early Detection

Early Screening

Hereditary Genetic Testing

Family Genetic Testing

Blood

Liquid Biopsy

Target Therapy

ctDNA

1. Target Therapy
2. Cancer Monitor

SOFIVA GENOMICS

Operating Performance

Operational Performance

Statements of Comprehensive Income of last 3 years



	(In Thousands of New Taiwan Dollars)		
	2021	2022	2023
Revenue	508,415	495,775	466,797
Gross Profit	176,813	148,988	129,908
Gross Profit (%)	34.78%	30.05%	27.83%
Opreating Income	35,240	3,787	(15,882)
Total Non-Opreating Income	28,453	43,562	24,785
Pre-Tax Income	63,693	47,349	8,903
Net Income	56,769	43,153	11,923
EPS	2.68	2.00	0.54

Revenue Trend：The Last 10 Quarters



SOFIVA GENOMICS

Revenue Trend：The Last 6 Months



SOFIVA GENOMICS

Investment Performance

(In Thousands of New Taiwan Dollars)

DIANTHUS CO.,Ltd			
Statements of Comprehensive Income			
	2021	2022	2023
Sales Revenue	599,944	689,795	695,831
Comprehensive Income	171,767	253,022	142,929
Capital Stock	895,000	895,000	895,000
Investment from Sofiva	148,250	148,250	148,250
Shareholding Ratio of Sofiva	16.56%	16.56%	16.56%
Investment Income of Sofiva	31,047	41,902	23,671



SOFIVA GENOMICS Co., Ltd.

www.sofivagenomics.com

T +886-2-2382-6615

F +886-2-2382-6617

Add No.27, Baoqing Rd., Zhongzheng Dist., Taipei City 100